Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.
Obes. Rev. 21:e12992 (2020)
In early childhood, individuals with Prader-Willi syndrome (PWS) experience excess weight gain and severe hyperphagia with food compulsivity, which often leads to early onset morbid obesity. Effective treatments for appetite suppression and weight control are currently unavailable for PWS. Our aim to further understand the pathogenesis of PWS led us to carry out a comprehensive search of the current and emerging therapies for managing hyperphagia and extreme weight gain in PWS. A literature search was performed using PubMed and the following keywords: “PWS” AND “therapy” OR “[drug name]”; reference lists, pharmaceutical websites, and the ClinicalTrials.gov registry were also reviewed. Articles presenting data from current standard treatments in PWS and also clinical trials of pharmacological agents in the pipeline were selected. Current standard treatments include dietary restriction/modifications, exercise, and growth hormone replacement, which appear to have limited efficacy for appetite and weight control in patients with PWS. The long-term safety and effectiveness of bariatric surgery in PWS remains unknown. However, many promising pharmacotherapies are in development and, if approved, will bring much needed choices into the PWS pharmacological armamentarium. With the progress that is currently being made in our understanding of PWS, an effective treatment may not be far off.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
7.310
3.175
9
21
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Hyperphagia ; Obesity ; Prader-willi Syndrome ; Therapy; Glucagon-like Peptide-1; O-acyltransferase Goat; Growth-hormone Therapy; Laparoscopic Sleeve Gastrectomy; Cannabinoid-1 Receptor Blocker; Monoamine Reuptake Inhibitor; Melanocortin-4 Receptor; Double-blind; Weight-loss; Acylated Ghrelin
Sprache
englisch
Veröffentlichungsjahr
2020
Prepublished im Jahr
2019
HGF-Berichtsjahr
2019
ISSN (print) / ISBN
1467-7881
e-ISSN
1467-789X
Zeitschrift
Obesity Reviews
Quellenangaben
Band: 21,
Heft: 5,
Artikelnummer: e12992
Verlag
Blackwell
Verlagsort
Oxford
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Diabetes and Obesity (IDO)
POF Topic(s)
90000 - German Center for Diabetes Research
Forschungsfeld(er)
Helmholtz Diabetes Center
PSP-Element(e)
G-501900-221
WOS ID
WOS:000504848700001
Scopus ID
85077842745
PubMed ID
31889409
Erfassungsdatum
2020-01-15